- Gilead Sciences (NasdaqGS:GILD) and Kite reported new CAR T cell therapy data for blood cancers at the 2026 ASH Annual Meeting.
- The update included 18 month follow up data for a potential multiple myeloma therapy candidate from Gilead's cell therapy pipeline.
- Kite also shared long term Yescarta outcomes in large B cell lymphoma, adding further detail on durability of clinical responses.
- These fresh CAR T results from ASH 2026 deserve to be weighed alongside the rest of the picture on Gilead. We have also flagged 2 warning signs for Gilead Sciences.
For investors tracking advances in complex therapies and the infrastructure that supports them, the broader trend is worth exploring via 53 AI infrastructure stocks.
Gilead Sciences, a US biopharmaceutical group with a market value of about $216.4b, focuses on medicines for unmet medical needs. These CAR T data points are directly relevant to how its oncology research pipeline might translate into future treatment options for blood cancers.
3 things going right for Gilead Sciences that this headline doesn't cover.
How does the ASH 2026 CAR T update change Gilead Sciences’ market opportunity in blood cancers?
The iMMagine 1 data for anito cel in relapsed or refractory multiple myeloma, now with 18 month follow up and an FDA priority review, positions Gilead and Kite in a roughly US$3.5b later line market that analysts already track in the Narrative. Long term Yescarta outcomes in large B cell lymphoma help Gilead argue for staying power in an established CAR T category where durability of response is a key commercial lever.
Does this ASH news actually shift the Gilead Sciences Narrative investors have been using?
The Narrative highlights oncology as a second growth engine, with cell therapy and antibody drug conjugates expected to broaden revenue beyond HIV. ASH 2026 reinforces that storyline by adding maturing data for anito cel alongside extended Yescarta follow up, which both support the catalyst that Gilead can build a sizeable oncology franchise rather than relying on a single asset or indication.
See how these catalysts shape Gilead Sciences' path to a $165 fair value.
What needs to happen next for this CAR T news to matter financially for Gilead Sciences?
For this update to become more than scientific momentum, investors will be watching the FDA decision on anito cel’s Biologics License Application and any launch timing the firm discloses if it is approved. Concrete indicators will include how quickly treatment centers adopt the therapy, how it competes within the relapsed or refractory multiple myeloma segment, and whether Yescarta usage trends reflect the long term outcome data just presented.
The Gilead Sciences detail most holders skip in plain sight
Price charts get all the attention, yet the real story for Gilead Sciences sits in where neutral analyst models say earnings and cash flows could land a few years from now. See where analysts expect Gilead Sciences to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com